BloodStream

BloodStream Media
  • 4.9 (43)
  • MENTAL HEALTH
  • UPDATED BIWEEKLY

BloodStream is an entertaining and informational podcast for the bleeding disorders community. Each week, hemophilia patient Patrick James Lynch and former non-profit director Amy Board are joined by advocacy leaders, medical experts, and other guests to discuss the latest news, scientific advancements, policy initiatives, and so much more. Subscribe wherever you listen, or search BloodStream Podcast on YouTube to catch every episode there. Produced by Believe Limited. Presenting sponsor: Takeda.

  1. Climbing the Seven Summits to raise awareness?!

    3D AGO ·  VIDEO

    Climbing the Seven Summits to raise awareness?!

    What does it look like to raise awareness from the top of the world? On the latest episode of BloodStream, Maia Meier joins our beloved hosts, Patrick and Amy, to talk about her mission to climb the Seven Summits through Project Elevate Her and bring visibility to women and girls living with bleeding disorders. From high-altitude expeditions to the everyday realities of advocacy, the conversation explores what it means to take up space in places where women with bleeding disorders have too often gone unseen. Listen now and subscribe to BloodStream Podcast wherever you get your shows.   Show Notes: Project Elevate Her   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more. Subscribe: The BloodStream Podcast   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter  BloodStream on Instagram BloodStream on LinkedIn BloodStream on TikTok

    27 min
  2. How the Patient Perspective Led to a Hemophilia Medical Breakthrough

    4D AGO

    How the Patient Perspective Led to a Hemophilia Medical Breakthrough

    Please see https://www.pfi.sr/HYMPAVZI_PI  for Full PI​ #HYMPAVZISponsored William S. Somers, Ph.D. is a biotherapeutics research and development leader with more than 30 years of experience across biotechnology and pharmaceutical organizations, including Pfizer.​ As a scientist living with hemophilia, Dr. Somers played a key role in driving the patient-centric and purposeful design of HYMPAVZI (marstacimab-hncq). This episode will explore how the patient perspective influenced the scientific journey, with a special focus on Will's research and why it was personally important for him to bring HYMPAVZI to people with hemophilia. To learn more and for safety information, visit HYMPAVZI.com.​ This post is directed to a U.S. audience and may not be suitable outside of the U.S. This video is intended to be viewed as it was originally produced in partnership with Pfizer. Remember, this content is for educational purposes only and is not intended to replace discussions with a healthcare provider.​ PP-HYM-USA-1071​ Show Notes:​ For prescribing information visit pfi.sr/HYMPAVZI_PI​ For information on how to navigate your treatment journey visit the shared decision-making guide here. Listen and subscribe where you get your podcasts!​ #Hemophilia HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HYMPAVZI safely and effectively. See full prescribing information for HYMPAVZI. HYMPAVZI (marstacimab-hncq) injection, for subcutaneous use Initial U.S. Approval: 2024 INDICATIONS AND USAGE HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. DOSAGE AND ADMINISTRATION See Full Prescribing Information for important dosing and administration instructions.  The recommended dosage of HYMPAVZI is: Loading dose: 300 mg (two 150 mg injections) by subcutaneous injection Maintenance dose: One week after the loading dose, initiate maintenance dosing of 150 mg every week by subcutaneous injection on the same day each week, at any time of day. Dose adjustment to 300 mg subcutaneous injection weekly can be considered. Factor VIII and factor IX products can be administered for the treatment of breakthrough bleeds in patients receiving HYMPAVZI. Do not use additional doses of HYMPAVZI to treat breakthrough bleeds.  Temporarily discontinue HYMPAVZI before major surgery.  DOSAGE FORMS AND STRENGTHS Injection: 150 mg/mL in a single-dose prefilled syringe  Injection: 150 mg/mL in a single-dose prefilled pen  CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS Thromboembolic Events: Thromboembolic events may occur. Interrupt HYMPAVZI prophylaxis if symptoms occur. Hypersensitivity: Hypersensitivity reactions may occur. In the event of a severe allergic reaction, discontinue HYMPAVZI. Embryofetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. ADVERSE REACTIONS Adverse reactions reported in ≥3% of HYMPAVZI-treated patients were injection site reaction, headache, and pruritus.  To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 12/2025

    21 min
  3. Lived experience across generations of bleeding disorders

    MAY 8 ·  VIDEO

    Lived experience across generations of bleeding disorders

    On the latest episode of BloodStream, we look at what is really underneath the words "I'm fine" and who it is serving to keep things that way. In I'm Fine, a family story across generations with bleeding disorders traces what has changed, what has not, and how honesty can begin to break cycles of silence that have long been passed down. What emerges is a closer look at resilience, inheritance, and the stories we are taught to minimize. We close out our plasma donation mini-series with donor Carver, highlighting the people behind every donation and the quiet consistency that keeps treatment possible. Plasma, perspective, and the moments where silence finally gives way to something more honest. Listen now and subscribe to BloodStream Podcast wherever you get your shows.   Show Notes: Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   I'm Fine is presented by @SanofiUS  Subscribe: The BloodStream Podcast   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter  BloodStream on Instagram BloodStream on LinkedIn BloodStream on TikTok

    27 min
  4. Plasma donors, RARE BLOOD, and advocacy wins

    APR 24

    Plasma donors, RARE BLOOD, and advocacy wins

    On this episode of BloodStream—our plasma donation series continues with a powerful second installment featuring donor Hannah and the story behind what it really means to give. We've also got a packed lineup: a look at momentum building at the WFH World Congress, policy progress led by State Senator Joseph Addabbo supporting families with rare disorders, and new momentum in storytelling as Sanofi backs additional documentaries spotlighting rare blood conditions. Plus, we dig into the bigger picture—how bleeding disorders impact entire families, the role creativity plays when navigating physical limitations, and the isolation that can come with not knowing someone who shares your experience. And don't miss a spotlight on The Red Ink Project and their virtual screening of Dismissed, a film bringing long-overdue visibility to women and girls with bleeding disorders. All that and more—this is BloodStream. Show Notes: NY State Senator Joseph Addabbo steps up for bleeding disorders Sanofi backs 2 more documentary films about rare blood disorders theredinkproject.org   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Subscribe: The BloodStream Podcast   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter  BloodStream on Instagram BloodStream on LinkedIn BloodStream on TikTok

    24 min
  5. What happened to HEMGENIX!? An update on gene therapy.

    APR 10

    What happened to HEMGENIX!? An update on gene therapy.

    CSL Behring just announced a global "stockout" of Hemgenix—what's happening, and what does it mean for patients? On this episode of BloodStream Podcast, we break down the news, launch our mini-series on plasma donation, and hear from Thomas Savage in our I'm Fine segment, sharing the highs, the lows, and the reality of living with a severe bleeding disorder.  Pain, perseverance, and the lessons learned along the way give a rare, unfiltered glimpse into life behind the headlines—reminding us all that every treatment, every donation, and every day matters. Show Notes: I'm Fine is presented by @SanofiUS  #bloodstreammedia #raredisease #bleedingdisorders #podcast #chronicdisease #hemophiliacommunity #advocacy   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more. Subscribe: The BloodStream Podcast   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter  BloodStream on Instagram BloodStream on LinkedIn BloodStream on TikTok

    34 min
  6. Understanding Hemophilia A & B with Inhibitors: SEVENFACT in Focus

    APR 3

    Understanding Hemophilia A & B with Inhibitors: SEVENFACT in Focus

    In this special partnered episode of the BloodStream Podcast, hosts Patrick James Lynch and Amy Board speak with hematologist Dr. Tami Singleton about hemophilia A and B with inhibitors, a complex condition that changes how bleeding episodes are treated. Dr. Singleton explains what inhibitors are, why they develop, and how they impact clotting and everyday life for patients and families. The conversation also explores SEVENFACT, a recombinant factor VIIa bypassing agent, including how it works and what patients should know about dosing and treatment planning. Click here to learn more about SEVENFACT.

    41 min
  7. 100 Years of vWD w/ Dr. Nathan Connell

    MAR 27

    100 Years of vWD w/ Dr. Nathan Connell

    This year marks 100 years since von Willebrand disease (vWD) was first described, and on this episode of BloodStream we take a closer look at how far the field has come. Our beloved hosts, Patrick and Amy happily welcome Dr. Nathan Connell, hematologist and leading expert in bleeding disorders, for a conversation about the past, present, and future of vWD. Together they explore how our understanding of the condition has evolved since its discovery, the challenges that remain in diagnosis and care, and why awareness still matters for the millions of people worldwide living with vWD. From early clinical observations to modern treatment approaches, Dr. Connell reflects on the milestones that have shaped care over the last century—and what the next hundred years could hold. Plus, a preview of what's coming next on BloodStream as we approach World Hemophilia Day.   Show Notes: Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   Subscribe: The BloodStream Podcast   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter  BloodStream on Instagram BloodStream on LinkedIn BloodStream on TikTok

    33 min
  8. Psychosocial support and bye bye, BioMarin

    MAR 13

    Psychosocial support and bye bye, BioMarin

    Bleeding disorders aren't just medical conditions — they're lived experiences shaped by resilience, community, and support. On this episode of BloodStream Podcast, Patrick James Lynch sits down with the WFH working group to explore why psychosocial care matters just as much as medicine and how human connections help people thrive.  Rocky Williams joins to share the power of positivity and what it truly means to be more than "fine," inspiring the bleeding disorders community to dream bigger, aim higher, and embrace life fully. We also break down a major shift in gene therapy: BioMarin's decision to pull Roctavian from the market, what it means for patients, and why preserving critical clinical data is essential for ongoing research and safety.  Tune in for a conversation that blends science, mindset, and community — because living with bleeding disorders is about more than treatments, it's about life itself. Show Notes: BioMarin pulls hemophilia gene therapy Roctavian WFH Gene Therapy Registry LevelsMatter.com   Presenting Sponsor: Takeda, visit bleedingdisorders.com to learn more.   I'm Fine is presented by @SanofiUS  #bloodstreammedia #raredisease #bleedingdisorders #podcast #chronicdisease #hemophiliacommunity #advocacy   Subscribe: The BloodStream Podcast   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on X/Twitter  BloodStream on Instagram BloodStream on LinkedIn BloodStream on TikTok

    48 min
See All (100)

4.9
out of 5
43 Ratings

About

BloodStream is an entertaining and informational podcast for the bleeding disorders community. Each week, hemophilia patient Patrick James Lynch and former non-profit director Amy Board are joined by advocacy leaders, medical experts, and other guests to discuss the latest news, scientific advancements, policy initiatives, and so much more. Subscribe wherever you listen, or search BloodStream Podcast on YouTube to catch every episode there. Produced by Believe Limited. Presenting sponsor: Takeda.

Information

More From BloodStream Media

You Might Also Like